Claims
- 1. A compound of the formula: ##STR40## or a pharmaceutically acceptable salt thereof, wherein Y is --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O-- CH.sub.2 S--; R is --CH or --CONH.sub.2 ;
- and R.sup.1 is a group of the formula: ##STR41## where R.sup.2 and R.sup.3 are each independently H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --(CH.sub.2).sub.n OH, halo, triflouormethyl, cyano, --(CH.sub.2).sub.n NR.sup.4 R.sup.5, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl, --CH(OH)(C.sub.1 -C.sub.4 alkyl, --C(OH)(C.sub.1 -C.sub.4 alkyl).sub.2, --SO.sub.2 NH.sub.2, --(CH.sub.2).sub.n CONR.sup.4 R.sup.5 or --(CH.sub.2).sub.n COO(C.sub.1 -C.sub.4 alkyl); R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl; n is 0, 1 or 2;
- and "Het" is pyridyl, pyrazinyl or thienyl.
- 2. A compound as claimed in claim 1 wherein R.sup.1 is: ##STR42## wherein R.sup.2 and R.sup.3 are each independently selected from H, halo, hydroxy, hydroxyethyl, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, and carbamoyl.
- 3. A compound as claimed in claim 1, wherein Y is --CH.sub.2 --, --(CH.sub.2).sub.2 -- or ----CH.sub.2 O--.
- 4. A compound as claimed in claim 3 wherein Y is --CH.sub.2 --.
- 5. A compound as claimed in claim 1 which is in the 3R- or 3RS- form.
- 6. A compound as claimed in claim 1 which is in the 3R-form.
- 7. A pharmaceutical composition for treating diseases associated with altered motility or tone of smooth muscle, comprising a muscarinic receptor antagonizing amount of a compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 8. A method of treatment of a human being to cure or prevent a disease associated with altered motility and/or tone of smooth muscle of the respiratory, gastrointestinal or urinary tract, comprising treating a human being in need of such treatment with a muscarinic receptor antagonizing amount of a compound of the formula (I), or a pharmaceutically acceptable salt or composition thereof, as claimed in claim 1.
- 9. The method of claim 8, wherein the disease is irritable bowel syndrome.
- 10. The 3R form of a compound of the formula ##STR43## where R is as defined in claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8825505 |
Nov 1988 |
GBX |
|
PCT/EP89/01300 |
Oct 1989 |
WOX |
|
Parent Case Info
This is a divisional application of application Ser. No. 07/678,941 filed Apr. 29, 1991, now U.S. Pat. No. 5,422,538, which is a National Stage filing under 35 U.S.C. .sctn.371 based on PCT/EP89/01300 filed internationally on Oct. 26, 1989.
US Referenced Citations (13)
Foreign Referenced Citations (6)
Number |
Date |
Country |
0178947 |
Apr 1986 |
EPX |
0178946 |
Apr 1986 |
EPX |
0228893 |
Jul 1987 |
EPX |
0235463 |
Sep 1987 |
EPX |
864458 |
Jun 1986 |
SAX |
0864522 |
Jun 1986 |
SAX |
Non-Patent Literature Citations (4)
Entry |
Chemical Abstracts; 90 (1979); Abstract No. 203878y. |
Katritzky et al.; "Comprehensive Heterocyclic Chemistry"; Pergamon Press; vol. 3, pp 959-960 (1984). |
Walsh et al.; J. Med. Chem., 32, 105-118 (1989). |
Goodman et al., The Pharmacologic Basis of Therapeutics, Pergamon Press, p. 123 (1990). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
678941 |
|
|